Posted by AGORACOM-JC
at 8:28 AM on Friday, February 18th, 2022
*AGORACOM Engagement Metrics Beat Benchmarks By 364% *AGORACOM Cashless Marketing Program Is 100% Compliant With TSXV, CSE and NEO
We are very proud to announce AGORACOM achieved another major milestone for the period December 31, 2021, when we surpassed 710 Million page views (81% AGORACOM / 19% Twitter) from 8.8 Million investors that visited 63.3 Million timesover the last 13 years.
These milestones are significant because they continue to demonstrate that AGORACOM is the primary home for serious small cap investors that want to discover their next great small cap investment. We owe much of this success to the following 2 major factors:
QUALITY OVER QUANTITY – Unlike small cap sites and major platforms that struggle with spam, profanity and overall nonsense, AGORACOM has implemented and strictly enforces it’s 6 Rules Of Use that create robust but civilized debate and discussion.
FOCUS. NOTHING BUT SMALL CAP – Despite the fact we are all in the finance industry, we don’t talk about macro finance, large cap or general economic news. Investors come to AGORACOM for just one thing – great small cap content .. and they don’t hesitate to show their love for us. AGORACOM ENGAGEMENT SHATTERS FINANCE BENCHMARKS BY 364%
AGORACOM small cap investors don’t just flip through pages, they invest a significant amount of time reading, studying and researching our small cap stocks like yours. …. And they do it far more than everywhere else. Here are the numbers:
PAGES READ PER VISIT > 364% HIGHER THAN INDUSTRY STANDARD
In a recent survey of 357 finance sites, LittleData determined the average number of pages read per visit was 2.0. The average number of pages read on AGORACOM are 9.28, which is 364% higher than the benchmark.
Moreover, when it came to the best 10% of all finance sites, AGORACOM has them beat hands down as well, with LittleData determining anything greater than 4.1 pages per visit represents the best 10% of all Finance sites. With AGORACOM registering 9.67 pages per visit for a 136% beat, it is fair to say AGORACOM is in elite status for engagement.
TIME SPENT PER VISIT > 161% HIGHER THAN INDUSTRY STANDARD
The average visitor to AGORACOM stays on the site for an average of 8 mins 23 secs. To put this into perspective, The Contentsquare Digital Experience Benchmark Report determined an average visit to financial services sites of 3 mins 13 secs, placing AGORACOM engagement 161% higher. Here are some comparables against some of the world’s biggest finance sites:
AGORACOM 8 mins 23 secs Wall Street Journal 3 mins 18 secs Marketwatch 5 mins 47 secs Motley Fool 1 mins 50 secs FOX Business 3 mins 39 secs Investing.com 5 mins 53 secs
HOW DOES AGORACOM CREATE INDUSTRY LEADING ENGAGEMENT?
The fight for investor attention is stronger than ever. Within the small cap industry investors are inundated with mountains of information from email to social media.
Moreover, the small cap industry is now facing stiff new competition for investor attention from the fast rising Web3 world of Cryptocurrencies, NFTs and Blockchains.
It’s enough to make both investors and issuers dizzy.
AGORACOM overcomes this challenge and wins the battle for investor attention by going the extra mile to create great content. While most firms communicate via “lazy linking” AGORACOM Founder and former lawyer George Tsiolis relies on his communications training to make sure the account management team delivers the following winning variety of content:
FORM – Blogs, Posts, Tweets, Comments, Videos, Audio, Graphics and GIFs
LENGTH – Ultra Long, Long, Medium, Short and Micro
PLATFORMS – YouTube, Twitter, LinkedIn, Facebook, Instagram, Spotify, Search, TikToK (yeah but no dancing!) … and of course our very own AGORACOM.com
Watch this concise but powerful 60-second video to get a great glimpse of our industry leading content machine. This unmatched variety in the form, length and distribution of our content removes all the noise for investors while providing clients with a complete digital marketing solution.
ZERO $ … AGORACOM CASHLESS AND 100% COMPLIANT PROGRAM
As a small cap company, your cash is invaluable and shouldn’t be used for anything other than operations and growth. You’ll be happy to know The AGORACOM Cashless, Shares For Services Program is fully compliant with the TSX Venture, CSE and NEO Exchanges. As such, it is considered the friendliest comp structure in the entire industry and can be summarized as follows:
Shares are issued in 5 X $20,000 installments over the twelve month term.
-Start Date -End Of Q1 -End Of Q2 -End Of Q3 -End Of Q4
-The number of shares issued is determined by the share price at each date. As the issuer share price goes higher, the number of shares issued to AGORACOM decreases.
-Each issuance comes with customary 4-month hold periods. As such, AGORACOM is a shareholder for at least 16 months (Q4 + 4 Months)
-Structure means AGORACOM becomes a long-term shareholder that is completely aligned with the Company
-$0 Cash + the full firepower of AGORACOM
CONCLUSION
Massive audience + industry leading engagement + industry leading content + $0 cash, 100% compliant shares for services
We are pleased to announce we have been selected by the Ketamine Research Foundation (KRF) to host a phase II clinical trial investigating ketamine-assisted psychotherapy (KAP) for adults with life-threatening illness (Conscious Dying/Conscious Living Trial).
“This study is an important addition to the clinical care and research opportunities for patients within the Psychedelic Palliative Care program that we are building at Novamind,” said Dr. Paul Thielking, Chief Scientific Officer and Principal Investigator at Novamind’s Murray research site. “I’ve worked with this population for most of my career and, unfortunately, I’ve sometimes felt limited in what I can offer my patients to ease their emotional distress. The findings will contribute to the evidence for using KAP with patients who have a life-threatening illness and offer new insights into alternative treatments.”
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the many facets of anger. They discuss the following: how conditioning affects how we process emotions like anger, the corrective emotional experience afforded by MDMA-assisted psychotherapy and much more.
The Huntsman Cancer Institute in Salt Lake City, Utah is investigating group psilocybin therapy as a treatment for anxiety and depression in cancer patients. Dr. Paul Thielking, who serves as the study’s lead therapist, explains that even just one dose of psilocybin could entirely shift the patient’s perspective on their illness and situation. Even more remarkable? The effects of those experiences seem to last—in some case, more than four years.
Microdosing. Does it work? Amidst increased buzz around the benefits of the practice, research continues to tackle this difficult question. This week, a new double-blind study revealed that microdosing with LSD produces “negligible changes in mood and cognition”, and there has been no research on the efficacy for people suffering from anxiety and depression. Check out National Geographic’s microdosing feature to learn more about current research, perspectives, and remaining questions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore the topic of depression and whether or not psychedelic medicine can help treat it. They discuss the following: depression and suicidal ideation, ketamine treatment for depression, the qualities to look for in a professional helper, and much more.
Chief Medical Officer, Dr. Reid Robison sits down with The Dales Report to discuss his involvement in a number of studies involving ketamine and other drugs that target the same mechanisms. Many of the questions he’s asked along the way focus on safety considerations and optimal conditions for treatment.
While classic psychedelics work towards FDA approval, global drug developers are moving beyond traditional plant medicines to focus their attention on the creation of novel “precision psychedelics”, compounds with shorter trips, less side effects, and, in some cases, no hallucinogenic component. Researchers are hopeful their efforts will increase access and scalability of psychedelic treatment. “I try to think of my mom,” one COMPASS chemist explains. “If she had to have this medication, what would I want for her as an ideal compound and ideal experience?”
100,000 overdose deaths occurred in the U.S. between April 2020 and April 2021. Despite the steady rise of overdose deaths in the U.S. over the last two decades, the latest data raises an alarm about the increased need for substance use disorder prevention and treatment. Novamind recently announced plans to develop an innovative substance use disorder program. We’re also hosting a clinical trial for ketamine-assisted psychotherapy + mindfulness for opioid use disorder. Read about it here.
We are pleased to announce that, further to our press release dated December 23, 2021, we have closed our acquisition of Arizona-based Foundations for Change, Inc., a mental health practice specialized in ketamine-assisted psychotherapy.
“We’re thrilled to welcome the team from Foundations,” commented Novamind CEO and Director, Yaron Conforti. “The Acquisition is an exciting opportunity for Novamind to expand the reach of our clinic network, bringing our model for innovative mental healthcare to a new market in Arizona.”
With the closing of the Acquisition, Foundations founder Jeff Edelman, MSN, APRN, PMHNP-BC, PMHCNS-BC, assumes the role of Medical Director at the Peoria and Phoenix clinic locations.
Mr. Edelman commented: “Joining Novamind is the right fit for our team and aligns with our mission to provide innovative and compassionate mental healthcare. I would like to thank our patients, partners and community for their ongoing support over the years. We look forward to integrating our team and operations with Novamind and benefiting from its deep expertise and infrastructure as we continue to serve a growing patient population.”
We are pleased to announce our participation in Citi’s Psychedelic Drug Video Call Series to be held virtually on January 25, 2022.
Neena Bitritto-Garg, Vice President Research Analyst, Biotech, at Citi, will host Novamind’s Chief Executive Officer, Yaron Conforti and Chief Medical Officer, Reid Robison, MD, MBA, for a fireside chat at 10:00 AM ET.
“Novamind has an established track record as a leader in commercializing psychedelic medicine and other innovative mental health therapies through a growing network of clinics and hosting an exciting pipeline of clinical trials for major drug developers,” said Mr. Conforti. “I look forward to introducing Citi’s clients to Novamind and expanding our relationships with a global base of institutional investors.”
To register for the call, please contact your Citi representative directly.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison explore whether or not psychedelic medicine can change your personality. They discuss the following: alter states for altered traits, “ego” and how psychedelic medicine can lead to personality changes, and much more.
In the latest issue of Mental Health Weekly, Chief Medical Officer Dr. Reid Robison discusses the benefits and barriers of psychedelic treatment and weighs in on the progress of MDMA & psilocybin research and legislative activities in the US.
Perceptions on the potential of psilocybin therapy are shifting in the medical community, according to a recent COMPASS Pathways-sponsored survey. “Severe mental illnesses, such as treatment-resistant depression, have affected too many people in society for too long. Physicians are looking for new approaches to accelerate the healing process, particularly for patients for whom current therapies have failed.”
A new study by Jay Nair and colleagues from MAPS PBC tries to answer the question of how psychedelic substances will be produced. This is an important step and still, “Many open questions remain about the legal framework that needs to materialize, who will distribute the medicines, and who will be qualified to provide the treatment.” Dr. Robison sat down with Mental Health Weekly for similar conversation.
Lucid News’ Itzhak Beery explores the role of shamanism in Western medicine. “Some psychotherapists feel pressured to offer this type of healing to their clients, who have heard about these magical treatments and hope for a short cut to relief. Most facilitators do not acknowledge the element of spirit or the unseen world.” We’ve also explored this question (and more) in a previous episode of the Psychedelic Frontiers Podcast. Listen to it again here.
We are pleased to unveil our clinic design concept to accommodate the unique requirements of psychedelic-assisted psychotherapy. The design concept will launch first in Novamind’s Park City, Utah location, and later across Novamind’s de novo clinics. Select design elements and principles will be integrated within existing clinic locations.
Inclusive and welcoming, the design concept enhances the patient experience at Novamind clinics, prioritizing patient safety and privacy, and utilizing evidence-based therapeutic elements to optimize patient care, including:
Biophilic designs that mimic nature and emphasize light interplay and neutral colour theory
Walking paths designed to minimize disruption and traffic across the clinic, creating a sense of privacy and tranquility
Curved treatment spaces, representing the protective space of cocoons, to facilitate the more sedentary experience of ketamine treatment
Larger treatment rooms to accommodate group therapy programs and support movement and more active patient behaviours associated with MDMA, psilocybin and other psychedelic medicines when approved by the FDA
To create the Design Concept, Novamind contracted DesignAgency, an internationally recognized interior design firm with clients that include the Four Seasons Hotels, MGM Resorts, Momofuku restaurants, Soho House and others. DesignAgency worked closely with Novamind’s clinical team to incorporate a host of therapeutic considerations into the design blueprint to achieve optimal patient experiences.
“We collaborated with Novamind’s clinical team and understood the importance of ‘set and setting’ in psychedelic medicine,” said Matt Davis, Co-Founder and Principal at DesignAgency. “The goal was to create spaces that allow patients to have a holistic experience and signal hope and healing well before they walk through the door.”
Dr. Reid Robison, Chief Medical Officer at Novamind, commented: “This new concept, combined with Novamind’s standard operating procedures, creates the most welcoming and effective healing environment possible. We wanted our clinics to be comforting, inviting and calming. With guidance from the DesignAgency team, we now have the blueprint to create spaces that elevate our patients’ healing experience.”
To see renderings of the Design Concept, click here.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison are joined by Dr. Amy de la Garza. Amy is the Substance Use Disorder Program Director at Novamind and the Medical Director of the Salt Lake City clinic. Amy is a board-certified family practice physician who for the last 10 years has been providing specialized integrative healthcare for behavioral health, substance use, and a variety of other conditions.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison discuss qualities and skills they think are essential for therapists who provide psychedelic-assisted psychotherapy.
We’re celebrating 8 months of the podcast with a GIVEAWAY on Instagram! Enter to win a sweatshirt featuring the audio waves from a fan-favorite episode of Psychedelic Therapy Frontiers.
This is big news for Canada overall. “Long-awaited amendments to Health Canada’s Special Access Program have finally been made, potentially opening the door to less onerous access to the medical access of psychedelics like psilocybin and MDMA for patients in need.” Our mission has always been to increase access to these life-changing therapies and drugs in safe and regulated settings. We celebrate this news and will continue to do our part to bring psychedelic medicine to as many people in need as possible.
PSYCH covers the year in psychedelic healthcare. “2021 was a seminal year for psychedelic medicine, with data released from groundbreaking clinical trials harnessing MDMA and psilocybin.” 2021 was special, but we can’t wait to work on making 2022 even more impactful for people around the world. For more great psychedelic content from PSYCH, download the third edition of the Psychedelics as Medicine Report here.
Dr. Reid Robison and the team at Novamind have spent years providing ketamine-assisted psychotherapy and seeing the positive benefits firsthand. It’s changed the lives of thousands of our patients. We recently published a story about how ketamine helped a mother struggling with severe depression and a struggling marriage. You can read it here. Seeing the results of this systematic review by the University of Exeter is both exciting and validating. “Ketamine therapy has a swift short-term effect on reducing symptoms of depression and suicidal thoughts, according to a review of all the available evidence.”
Posted by AGORACOM-JC
at 5:25 PM on Thursday, January 6th, 2022
The global e-commerce market surpassed $9 TRILLION in 2019 … and is scheduled to grow by a CAGR of 14% into 2027 … But mega brands control almost 70% of the US market alone and are using their strength to win even more market … making it harder for SMBs to compete in this massive market.
Logiq …. a public company for just 4 months…. is an award-winning e-commerce and fintech solutions company that is addressing that problem by helping drive e-commerce for SMBs around the world … with revenues of $37.9M in 2020 …. from 2 divisions:
AppLogiq (Agreement finalized to Transfer AppLogiq Assets into Publicly Traded Subsidiary) – In Southeast Asia AL offers a mobile application development platform as-a-service which enables hundreds of thousands of SMBs to create mobile apps with little technical expertise or know-how … Offered across Southeast Asia, Europe and U.S. in 14 languages .. …. also offers a mobile fintech payment platform (PayLogiQ) and a hyper-local food delivery service (GoLogiq)
DataLogiq – provides a data-driven, end-to-end e-commerce marketing solution that integrates AI to help SMBs in need of online marketing solutions.
Financial Highlights:
2020 revenue of $37.9 million … 31% CAGR since 2016
Revenue H1-21 $16.4 million
Revenue Q2-21 $8.3 million …
margin of 29.5%
up 16.4 percentage points from the year-ago quarter.
Revenue Q3-21 $7.8 million
margin for DataLogiq: improved from 18.9% to 28.2%.
margin for AppLogiq: improved from 12.1% to 31.7%.
Q4-21 Revenue Estimate: $12.3 million, up 87% vs Q4-20
Gross margin expected to 34.0% vs 29.5% in the previous Q / 21.1% in Q4-20
Brent Suen, president of Logiq commented,
“Our improving revenue performance throughout 2021 demonstrates our team’s commitment to driving a transformation of our business overall and providing visibility on future profitability. As we refocused our efforts on higher quality, more profitable revenue streams and adjusted to the changing market dynamics, we also drove strong gross margin improvement every quarter of 2021. In fact, our gross margin more than doubled in Q4 2021 compared to the full year of 2020.”
Suen continued,
“We believe this strong progress across the board is keeping us on the path to profitability for both of our business segments,” continued Suen. “It also advances our plans to separate our DataLogiq and AppLogiq businesses into two independent publicly traded companies as another way to further unlock shareholder value.”
Now sit back, relax and watch this powerful interview.
Posted by AGORACOM-JC
at 1:40 PM on Thursday, January 6th, 2022
Valeo Pharma is already a successful, revenue-generating, small-cap Canadian pharmaceutical company that acquires the Canadian rights to commercialized drugs in other parts of the world that don’t have Canada on their radar as a target market.
This “in-license” business model is ingenious because it means ZERO developmental or clinical risk, which is the downfall of most small-cap pharma companies.
The company released stellar a Q3 with the following highlights:
Record revenues of $5.7 million for Q3 2021, up 280% over Q3 2020 and 114% over prior quarter.
Record gross margin of $2.2 million , up 1602% over Q3 2020 and 204% over prior quarter.
Record 9 months revenues at $10.2 million , up 94%
Approved by Health Canada for immune support, is now available for sale in approximately 300 stores under the Loblaw’s banners including:
Loblaws
Dominion,
Zehrs,
Fortinio’s,
Your Independent Grocer and Superstore
Steve Saviuk , CEO commented,
We are very pleased to announce that Hesperco is now available in over 300 Loblaw banner stores. The immune support properties of hesperidin, the sole medicinal ingredient contained in Hesperco capsules, has been well documented in numerous scientific publications. We are also encouraged by the results of the Hesperidin Covid-19 clinical trial which has recently been submitted for publication. The study concluded that hesperidin could have beneficial effects and may help reduce certain Covid-19 symptoms. The publication further suggested that earlier treatment of longer duration and/or higher dosage should be studied.”
Posted by AGORACOM-JC
at 6:11 PM on Wednesday, January 5th, 2022
The genesis of Liquid Avatar Technologies is a global blockchain & personal identity solutions company specializing in empowering individuals to manage, control and generate value from their biometrically-verified digital Identity, which also provides businesses and governments the ability to easily integrate digital wallets and digital identity solutions through its Liquid Avatar platform (www.liquidavatar.com)
And if the story ended there, that would be more than enough to build a company on.
However, as the digital universe has continued to expand, there is an ever-increasing need to verify online identity as governments and enterprises around the world prepare for the shift. For example:
In early 2021 Google announced a major shift away from precision-targeting of ads based on everything you do on the internet
The Ontario Government released its Digital Strategy, with key themes including the launch of Digital ID credentials.
“Ontario is one of the first jurisdictions in North America to announce that it will issue and enable digital credentials – and it has been a great experience working with the government on this both directly and through our role in membership organizations like the Trust Over IP Foundation,
As a result, the Liquid Avatar Verifiable Credentials Ecosystem (LAVCE) is being built to support all participants in a digital credential ecosystem. Almost immediately, Liquid Avatar announced a big win here by partnering with the Ontario Convenience Stores Association (OCSA) To Provide Digital Age-Verification Solutions To Over 8,000 Stores.
Again, if the story ended there, Liquid Avatar would have the makings of a potentially massive tech company.
But with the rise of NFTs and the Metaverse, both of which strongly rely on digital identity, the Company continued to expand its core digital identity technology into these areas and registered major successes, including $1,000,000 in Preliminary Gross Revenues for its Aftermath Islands Metaverse.
“Our in-market businesses continued to perform above expectations for Q4, and we remain optimistic, while cautious, as these are still early days in the Company’s transformation to an active revenue organization. We have started to witness online acceptance of digital identity programs, which are at the core of all our solutions, and both avatar and metaverse activities are gaining traction, creating opportunities for early revenue there, as the industry embraces the future of Web 3.0. Our goal is to continue to create value for all our stakeholders.”
If you believe in the future of Web3 (blockchain, crypto, tokens, NFTs and the Metaverse) and looking for a small cap company to help you participation in it, then look no further than Liquid Avatar.
Watch this powerful interview with CEO David Lucatch.
Posted by AGORACOM-JC
at 4:24 PM on Thursday, December 30th, 2021
FOBI AI is a global leader in digital wallet pass technology that delivers real-time data analytics and engagement through artificial intelligence to drive customer activation and engagement in stores, stadiums, arenas, hotels and other large venues around the world.
More than just lip service, FOBI AI is firing on all cylinders. Here are just some of the highlights from December:
Posted by AGORACOM-JC
at 10:18 AM on Saturday, December 25th, 2021
The Roundup
A weekly summary of Novamind news and media
Dr. Steve Thayer with an important reminder that, for some, the holidays can be a difficult time of year for many reasons. He shares tips to care for our mental health and wellbeing over the holidays.
We are pleased to announce the signing of a definitive agreement to acquire Arizona-based Foundations for Change, a mental health practice specialized in ketamine-assisted psychotherapy, from its sole stockholder, Jeff Edelman. The transaction is subject to regulatory approvals and is expected to close in January 2022.
Opened in 2017 by Jeff Edelman, Foundations currently operates one outpatient mental health clinic in Peoria, Arizona with an annual revenue run rate in excess of US$800,000 and owns a second, larger location in Phoenix that is scheduled to open in early 2022. Foundations will temporarily operate as “Foundations for Change by Novamind” until the Company completes its recently announced rebrand. Mr. Edelman will continue in a leadership capacity as Medical Director for both clinics. Mr. Edelman is double board-certified Family Psychiatric-Mental Health Nurse Practitioner and a Child and Adolescent Psychiatric-Mental Health Clinical Nurse Specialist. As a former military combat veteran, who served in the US Army 55th Medical Co. Combat Stress Control unit, Mr. Edelman has special expertise in treating military veterans and first responders who struggle with stress and trauma.
In this episode of the Psychedelic Therapy Frontiers podcast, Dr. Steve Thayer and Dr. Reid Robison catch up after their recent trip to the “Horizons: Perspectives on Psychedelics” conference in New York. Stay tuned next week for our last episode of 2021 and a special PTF podcast contest and giveaway.
NBC News reports on a first-of-its kind clinical trial at the University of Washington School of Medicine to treat 30 medical professionals experiencing depression with a dose of synthetic psilocybin combined with psychotherapy. Some say that even five years ago, this would have been considered taboo. “That medical researchers are turning toward psilocybin to treat colleagues is representative of a growing curiosity and acceptance of the drug among those in the medical establishment.” We’re seeing that openness, too, through our Frontline KAP clinical pilot to help healthcare workers heal.
